Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar) (Q-BC)
|ClinicalTrials.gov Identifier: NCT00504361|
Recruitment Status : Completed
First Posted : July 20, 2007
Last Update Posted : May 2, 2016
|Condition or disease|
|Asthma COPD Interstitial Lung Disease Cystic Fibrosis Lung Cancer|
This protocol is designed to collect a small amount of blood for extraction of DNA (genetic material) for the study of the genetic basis of lung disease. The study population will include individuals with known lung diseases and controls without lung disease. Individuals in the study population will be individuals at the Hamad Medical Corporation, Qatar (HMC), as well as other individuals recruited for this study. In this protocol, researchers will survey medical records of patients with chronic lung disease, in order to study the clinical characteristics of these individuals, and the researchers will collect blood to evaluate the genetic characteristics of individuals with chronic lung diseases including asthma, and COPD (chronic obstructive pulmonary disease), pulmonary fibrosis, and lung cancer. The researchers will also collect blood samples of individuals without lung disease to serve as control.
This protocol, to be carried out at Weill Cornell Medical College - Qatar and Hamad Medical Corporation, Qatar, parallels a similar approved protocol IRB #0508008095, entitled, "Collection of Blood for Gene Expression/Genomic Studies in Individuals with Chronic Lung Diseases", ongoing at Weill Cornell Medical College - New York.
|Study Type :||Observational|
|Actual Enrollment :||600 participants|
|Observational Model:||Case Control|
|Official Title:||Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases (Qatar)|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||May 2012|
|Actual Study Completion Date :||May 2012|
1: Lung Disease
Individuals with at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; and (7) individuals suspected of history of lung diseased based on history and/or physical examination
2: Normal Control
Individuals without a history of lung disease.
- Genomic DNA will be extracted, and genome wide SNP analysis and promoter sequences for genes will be obtained. [ Time Frame: 5 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00504361
|Hamad Medical Corporation|
|Principal Investigator:||Ronald G Crystal, MD||Weill Cornell Medical College, NY and Qatar|